key: cord-0816333-2xy9fw3r
authors: Vicent, Marta González; Martinez, Antonio Pérez; Trabazo del Castillo, María; Molina, Blanca; Sisini, Luisa; Morón‐Cazalilla, Georgina; Díaz, Miguel Ángel
title: COVID‐19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH)
date: 2020-06-23
journal: Pediatr Blood Cancer
DOI: 10.1002/pbc.28514
sha: c53a2feb04c83e83ae42a97f94ca3a2058754003
doc_id: 816333
cord_uid: 2xy9fw3r

nan

To the Editor: COVID-19 mortality risk factors have been defined, including comorbidities such as cardiovascular disease, hypertension, and diabetes. 1 Cancer also appears to increase both incidence and risk of adverse events. So, the incidence of COVID-19 in children with cancer in Madrid has recently been reported and is 1.3% higher than in the general pediatric population. 2 Table 1 . We identified eight children with a median age of 10 years old (range 1-12), which is an incidence of 3% of the pediatric HSCT performed annually in Spain. A total of seven recipients (87%) were male. Median Lansky score was 80% and ECOG scale of 1. The underlying disease was immunodeficiency in three cases (37.5%) and leukemia/myelodysplasia in the other five (62.5%). Graft type of donor was a human leukocyte antigen (HLA)identical unrelated donor in three cases (37.5%), a haploidentical donor in three (37.5%), and a HLA-identical sibling donor in the other two cases (25%). Median presentation time of COVID-19 was 18 months (range 1 month-2 years) after HSCT.

The most common symptoms were fever in five patients (62.5%), respiratory symptoms in four (50%), and diarrhea in the other two (25%). None of the patients were asymptomatic. Five patients (62%) had abnormal radiographic findings, mainly bilateral multifocal opacities and one of them developed alveolar hemorrhage. Three patients (37.5%) had viral coinfections: coronavirus NL63, rhinovirus + parainfluenza 4, and influenza B + rhinovirus + parainfluenza 1.

Two patients (25%) were hospitalized due to the COVID-19 infection, three patients (37.5%) were already hospitalized, and three patients (37.5%) were managed in the outpatient clinic.

One patient had acute graft-versus-host disease (GvHD) grade II, one had chronic GvHD, and one had engraftment syndrome during COVID-19 infection. These three patients were taking steroids.

The laboratory results are detailed in Supplemental Table S1 . Immunodeficiency scoring index (ISI score) developed for respiratory viral infections was used to categorize severity. 3 There was a correlation between the virus clearance time and the ISI score. Furthermore, patients with the highest ISI score (moderate-severe risk) required admission to the intensive care unit (ICU).

Regarding treatment, most patients (75%) received hydroxychloroquine. The two more severe patients received hydroxychloroquine combined with different drugs such as azithromycin, remdesivir, lopinavir/ritonavir, tocilizumab, siltuximab, and anakinra. In a severely ill child, coronavirus PCR was negative after memory T cell adoptive therapy obtained from his HLA identical donor. Two patients did not receive any treatment. Treatment details are shown in Table S2 . Although this study has the limitations of being a short case series, there are several conclusions from the results.

Firstly, the incidence of COVID-19 is also lower after HSCT in children than in adults, 4 as it has been published in the general population. This is probably because angiotensin enzyme converting 2 (ACE2) expression may be lower in pediatric population and because of the presence of other common respiratory viruses in children that compete with it. 5 Secondly, most cases in our series also occur in boys, similar to studies showing that males are more susceptible to SARS-CoV infection than females because of a protective effect for estrogen receptor. 1 Thirdly, immunodeficiencies have a higher risk of COVID-19 since they account for more than a third of cases, when they only account for 10% of the indication for pediatric HSCT. This may be due to the lack of 

Cardiovascular disease, drug therapy, and mortality in COVID-19

COVID-19 infection in children and adolescents with cancer in Madrid

Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections

Children with COVID-19 in pediatric emergency departments in Italy

COVID-19 pathophysiology: a review

Hematologic parameters in patients with COVID-19 infection

development of thymus in these patients, with significant alteration of cellular immunity. 6 So, the quantity and type of affected T lymphocytes seems to be more decisive for COVID-19, with lowest ratio CD4/CD8 in our severely ill patients.And finally, the ISI score is very useful to assess the need for treatment and the prognosis of patients with COVID-19.

The authors declare that there is no conflict of interest.